The clinicopathologic and prognostic significance of CD44+/CD24−/low and CD44−/CD24+ tumor cells in invasive breast carcinomas

Mylona, Eleni; Giannopoulou, Ioanna; Fasomytakis, Emmanouil; Nomikos, Alexandros; Μagkou, Christina; Bakarakos, Panagiotis; Nakopoulou, Lydia

doi:10.1016/j.humpath.2007.12.003

Cited by 135 publications

(111 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One set of identifying proteins used to define possible cancer stem cells in breast cancer are the combination of CD44 ϩ /CD24 Ϫ /lin Ϫ , 22 though it has been shown that this marker set is not relevant in terms of prognostic and predictive value after analyzing breast cancer tissue for these proteins. 44 ALDH1 is of special interest, because it is an enzyme crucial for embryogenic development but also necessary for normal differentiation of stem cells. ALDH1 has been shown to identify cells with characteristics of stem cells and/or early progenitor cells for normal breast epithelium as well as breast cancer.…”

Section: Discussionmentioning

confidence: 99%

In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis

Neumeister

Agarwal

Bordeaux

et al. 2010

The American Journal of Pathology

138

100

View full text Add to dashboard Cite

A subset of cells, tentatively called cancer stem cells (CSCs), in breast cancer have been associated with tumor initiation, drug resistance, and tumor persistence or aggressiveness. They are characterized by CD44 positivity, CD24 negativity, and/or ALDH1 positivity in flow cytometric studies. We hypothesized that the frequency or density of these cells may be associated with more aggressive tumor behavior. We borrowed these multiplexed, flow-based methods to develop an in situ method to define CSCs in formalin-fixed paraffin-embedded breast cancer tissue, with the goal of assessing the prognostic value of the presence of CSCs in breast cancer. Using a retrospective collection of 321 nodenegative and 318 node-positive patients with a mean follow-up time of 12.6 years, we assessed TMAs using the AQUA method for quantitative immunofluorescence. Using a multiplexed assay for ALDH1, CD44, and cytokeratin to measure the coexpression of these proteins, putative CSCs appear in variable sized clusters and in 27 cases (of 490), which showed significantly worse outcome (log rank P ‫؍‬ 0.0003). Multivariate analysis showed that this marker combination is independent of tumor size, histological grade, nodal status, ER-, PR,-and HER2-status. In this cohort, ALDH1 expression alone does not significantly predict outcome. We conclude that the multiplexed method of in situ identification of putative CSCs identifies high risk patients in breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis

Neumeister

Agarwal

Bordeaux

et al. 2010

The American Journal of Pathology

138

100

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that BCSCs are associated with the basal-like molecular subtype of breast cancer and a poor clinical outcome (26,27). However, Mylona et al (28) revealed that BCSCs are associated with a lack of lymph node metastasis and an improved clinical outcome. Furthermore, Abraham et al (29) reported that BCSCs were not associated with the clinical outcome.…”

Section: Discussionmentioning

confidence: 99%

Association between inflammation and cancer stem cell phenotype in breast cancer

Jeong

Park

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

“…-/low имеют доказанные признаки стволовости, и находка данного фе-нотипа клеток сопровождается плохим прогнозом [15]. СОК ответственны за инициацию опухолевого процесса, его течение и метастазирование.…”

Section: Cd24unclassified

Tumor stem cells in breast cancer

et al. 2015

View full text Add to dashboard Cite

The clinicopathologic and prognostic significance of CD44+/CD24−/low and CD44−/CD24+ tumor cells in invasive breast carcinomas

Cited by 135 publications

References 17 publications

In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis

In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis

Association between inflammation and cancer stem cell phenotype in breast cancer

Tumor stem cells in breast cancer

Contact Info

Product

Resources

About